RxDoctor Payments Data

Frederick Asare, MD

Internal Medicine · Fayetteville, NCNPI 1821195090

Payments from drug & device makers

$85,963in general payments, 2019–2025

Across 171 payments — averaging $502.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$83K
  • Pfizer$457
  • GSK$359
  • AstraZeneca$279
  • Novo Nordisk$248
  • Amgen$207
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$82,66796%
  • Travel & lodging$1150%
  • Food & beverage$2,7073%
  • Education$4751%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,963 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$88,376
Medicare patients
331
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide82$114,972
OzempicSemaglutide102$97,975
EliquisApixaban88$90,027
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$43,816
JanuviaSitagliptin Phosphate21$33,601
LinzessLinaclotide45$29,607
FarxigaDapagliflozin Propanediol19$20,931
XareltoRivaroxaban13$20,384
JardianceEmpagliflozin12$12,953
JanumetSitagliptin Phos/Metformin Hcl16$9,576
Tresiba Flextouch U-200Insulin Degludec15$9,209
SymbicortBudesonide/Formoterol Fumarate36$8,979
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,512
Combivent RespimatIpratropium/Albuterol Sulfate14$7,034
Breo ElliptaFluticasone/Vilanterol15$5,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$65$114,97282 claims
Novo NordiskOzempic$248$97,975102 claims
PfizerEliquis$457$90,02788 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$359$57,97882 claims
MerckJanuvia, Janumet$12$43,17837 claims
AstraZenecaFarxiga, Symbicort$279$29,91055 claims
AbbVieLinzess$69$29,60745 claims
Johnson & JohnsonXarelto$130$20,38413 claims
Boehringer IngelheimJardiance, Combivent Respimat$76$19,98726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →